{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T15:41:51Z","timestamp":1742398911652},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T00:00:00Z","timestamp":1450051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T00:00:00Z","timestamp":1450051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ongoing research and technology developments hold the promise of rapid production and large-scale deployment of strain-specific or cross-protective vaccines for novel influenza viruses. We sought to investigate the impact of early vaccination on age-specific attack rates and evaluate the outcomes of different vaccination strategies that are influenced by the level of single or two-dose vaccine-induced protections. We developed and parameterized an agent-based model for two population demographics of urban and remote areas in Canada. Our results demonstrate that there is a time period before and after the onset of epidemic, during which the outcomes of vaccination strategies may differ significantly and are highly influenced by demographic characteristics. For the urban population, attack rates were lowest for children younger than 5 years of age in all vaccination strategies. However, for the remote population, the lowest attack rates were obtained for adults older than 50 years of age in most strategies. We found that the reduction of attack rates following the start of vaccination campaigns during the epidemic depends critically on the disease transmissibility, suggesting that for a sufficiently high transmissibility, vaccine delivery after the onset of epidemic has little or no effect, regardless of the population demographics.<\/jats:p>","DOI":"10.1038\/srep18062","type":"journal-article","created":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T10:17:56Z","timestamp":1450088276000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Strategies for Early Vaccination During Novel Influenza Outbreaks"],"prefix":"10.1038","volume":"5","author":[{"given":"M.","family":"Laskowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Charland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. M.","family":"Moghadas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,14]]},"reference":[{"key":"BFsrep18062_CR1","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1086\/375056","volume":"36","author":"D Fedson","year":"2003","unstructured":"Fedson, D. Pandemic influenza and the global vaccine supply. Clin. Infect. Dis. 36, 1552\u20131561 (2003).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep18062_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1473-3099(04)01105-3","volume":"4","author":"I Stephenson","year":"2004","unstructured":"Stephenson, I., Nicholson, K., Wood, J., Zambon, M. & Katz J. Confronting the avian influenza threat: Vaccine development for a potential pandemic. The Lancet Infect. Dis. 4, 499\u2013509 (2004).","journal-title":"The Lancet Infect. Dis."},{"key":"BFsrep18062_CR3","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1128\/CMR.00097-12","volume":"26","author":"S Wong","year":"2013","unstructured":"Wong, S. & Webby, R. Traditional and new influenza vaccines. Clin. Microbiol. Rev. 26, 476\u2013492 (2013).","journal-title":"Clin. Microbiol. Rev."},{"key":"BFsrep18062_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10156-006-0453-Z","volume":"12","author":"H Oshitani","year":"2006","unstructured":"Oshitani, H. Potential benefits and limitations of various strategies to mitigate the impact of an influenza pandemic. J. Infect. Chemother. 12, 167\u2013171 (2006).","journal-title":"J. Infect. Chemother"},{"key":"BFsrep18062_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-7-208","volume":"7","author":"J Aledort","year":"2007","unstructured":"Aledort, J., Lurie, N., Wasserman, J. & Bozzette, S. Non-pharmaceutical public health interventions for pandemic influenza: An evaluation of the evidence base. BMC Public Health 7, 1\u20139 (2007).","journal-title":"BMC Public Health"},{"key":"BFsrep18062_CR6","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1016\/j.vaccine.2011.02.077","volume":"29","author":"FM LaForce","year":"2011","unstructured":"LaForce, F. M. Technology transfer to developing country vaccine manufacturers to improve global influenza vaccine production: a success story and a window into the future. Vaccine 29, A1 (2011).","journal-title":"Vaccine"},{"key":"BFsrep18062_CR7","unstructured":"World Health Organization, Influenza. http:\/\/www.who.int\/influenza\/vaccines\/en\/ (date of access: 30\/05\/2015)."},{"key":"BFsrep18062_CR8","doi-asserted-by":"publisher","first-page":"e92153","DOI":"10.1371\/journal.pone.0092153","volume":"9","author":"DM Skowronski","year":"2014","unstructured":"Skowronski, D. M. et al. Low 2012\u201313 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS ONE 9: e92153 (2014).","journal-title":"PLoS ONE"},{"key":"BFsrep18062_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1017\/S1466252312000175","volume":"13","author":"Q Chen","year":"2012","unstructured":"Chen, Q., Madson, D., Miller, C. & Harris, D. Vaccine development for protecting swine against influenza virus. Animal Health Res. Rev. 13, 181\u2013195 (2012).","journal-title":"Animal Health Res. Rev"},{"key":"BFsrep18062_CR10","unstructured":"Centers for Disease Control and Prevention, Cell-based flu vaccines, http:\/\/www.cdc.gov\/flu\/protect\/vaccine\/cell-based.htm. Updated (2013). (date of access: 7\/8\/2013)."},{"key":"BFsrep18062_CR11","unstructured":"US Food and Drug Administration Flublok, http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm335836.htm (date of access: 30\/05\/2015)."},{"key":"BFsrep18062_CR12","doi-asserted-by":"publisher","first-page":"7733","DOI":"10.1016\/j.vaccine.2011.07.128","volume":"29","author":"JJ Treanor","year":"2011","unstructured":"Treanor, J. J. et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok\u00ae) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 29, 7733\u20137739 (2011).","journal-title":"Vaccine"},{"key":"BFsrep18062_CR13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nm0695-583","volume":"1","author":"H Donnelly","year":"1995","unstructured":"Donnelly, H. et al. Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus. Nature Med. 1, 583\u2013587 (1995).","journal-title":"Nature Med."},{"key":"BFsrep18062_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.clim.2014.08.003","volume":"154","author":"N Landry","year":"2014","unstructured":"Landry, N. et al. Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. Clin. Immunol. 154, 164\u2013177 (2014).","journal-title":"Clin. Immunol."},{"key":"BFsrep18062_CR15","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1056\/NEJMc1313186","volume":"369","author":"LF Fries","year":"2013","unstructured":"Fries, L. F., Smith, G. E. & Glenn, G. M. A recombinant virus-like particle influenza A (H7N9) vaccine. New Engl. J. Med. 369, 2564\u20132566 (2013).","journal-title":"New Engl. J. Med"},{"key":"BFsrep18062_CR16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1467-7652.2009.00496.x","volume":"8","author":"MA D\u2019Aoust","year":"2010","unstructured":"D\u2019Aoust, M. A. et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J. 8, 607\u2013619 (2010).","journal-title":"Plant Biotechnol J."},{"key":"BFsrep18062_CR17","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1056\/NEJMoa070844","volume":"357","author":"KL Nichol","year":"2007","unstructured":"Nichol, K. L., Nordin, J. D., Nelson, D. B., Mullooly, J. P. & Hak, E. Effectiveness of influenza vaccine in the community-dwelling elderly. New Engl. J. Med. 357, 1373\u20131381 (2007).","journal-title":"New Engl. J. Med"},{"key":"BFsrep18062_CR18","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/S0264-410X(02)00041-5","volume":"20","author":"T Vu","year":"2002","unstructured":"Vu, T., Farish, S., Jenkins, M. & Kelly, H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 20, 1831\u20131836 (2002).","journal-title":"Vaccine"},{"key":"BFsrep18062_CR19","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S0140-6736(05)67339-4","volume":"366","author":"T Jefferson","year":"2005","unstructured":"Jefferson, T. et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. The Lancet 366, 1165\u20131174 (2005).","journal-title":"The Lancet"},{"key":"BFsrep18062_CR20","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/S0264-410X(03)00070-7","volume":"21","author":"KL Nichol","year":"2003","unstructured":"Nichol, K. L. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 21, 1769\u20131775 (2003).","journal-title":"Vaccine"},{"key":"BFsrep18062_CR21","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1001\/jama.284.13.1677","volume":"284","author":"ES Hurwitz","year":"2000","unstructured":"Hurwitz, E. S. et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA 284, 1677\u20131682 (2000).","journal-title":"JAMA"},{"key":"BFsrep18062_CR22","first-page":"e001614","volume":"2","author":"LC Mostaco-Guidolin","year":"2012","unstructured":"Mostaco-Guidolin, L. C., Bowman, C. S., Greer, A. L. Fisman, D. N. & Moghadas, S. M. Transmissibility of the 2009 H1N1 pandemic in remote and isolated Canadian communities: a modelling study, Brit. Med. J.\u2013Open 2, e001614 (2012).","journal-title":"Brit. Med. J.\u2013Open"},{"key":"BFsrep18062_CR23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1186\/1756-0500-4-537","volume":"4","author":"LC Mostaco-Guidolin","year":"2011","unstructured":"Mostaco-Guidolin, L. C., Greer, A. L., Sander, B., Wu, J. & Moghadas, S. M. Variability in transmissibility of the 2009 H1N1 pandemic in Canadian communities. BMC Res. Notes 4, 537 (2011).","journal-title":"BMC Res. Notes"},{"key":"BFsrep18062_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1503\/cmaj.091807","volume":"182","author":"AR Tuite","year":"2010","unstructured":"Tuite, A. R. et al. Estimated epidemiologic parameters and morbidity associated with pandemic H1N1 influenza. CMAJ 182, 131\u2013136 (2010).","journal-title":"CMAJ"},{"key":"BFsrep18062_CR25","unstructured":"Institute of Medicine (US) Committee on Review of Priorities in the National Vaccine Plan. Priorities for the National Vaccine Plan. Washington (DC): National Academies Press (US), 2010. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK220059\/ (date of access: 30\/05\/2015)."},{"key":"BFsrep18062_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10588-008-9027-1","volume":"14","author":"SM Mniszewski","year":"2008","unstructured":"Mniszewski, S. M., Del Valle, S. Y., Stroud, P. D., Riese, J. M. & Sydoriak, S. J. Pandemic simulation of antivirals + school closures: buying time until strain-specific vaccine is available. Comput. Math. Organiz. Theory 14, 209\u2013221 (2008).","journal-title":"Comput. Math. Organiz. Theory"},{"key":"BFsrep18062_CR27","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/infdis\/jir328","volume":"204","author":"B Lasko","year":"2011","unstructured":"Lasko, B. et al. Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03A-adjuvanted vaccination in adults. J. Infect. Dis. 204, 574\u2013581 (2011).","journal-title":"J. Infect. Dis."},{"key":"BFsrep18062_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/srep00105","volume":"1","author":"M Laskowski","year":"2011","unstructured":"Laskowski, M., Mosta\u00e7o-Guidolin, L. C., Greer, A. L., Wu, J. & Moghadas, S. M. The impact of demographic variables on disease spread: influenza in remote communities. Sci. Rep. 1, 105 (2011).","journal-title":"Sci. Rep"},{"key":"BFsrep18062_CR29","doi-asserted-by":"publisher","first-page":"20365","DOI":"10.1073\/pnas.0911580106","volume":"106","author":"JA Greenbaum","year":"2009","unstructured":"Greenbaum, J. A. et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc. Nat. Acad. Sci. USA 106, 20365\u201320370 (2009).","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"BFsrep18062_CR30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1750-2659.2010.00161.x","volume":"4","author":"VRSK Duvvuri","year":"2010","unstructured":"Duvvuri, V. R. S. K. et al. Highly conserved cross\u2013reactive CD4+ T\u2013cell HA\u2013epitopes of seasonal and the 2009 pandemic influenza viruses, Influenza and Other Respiratory Viruses 4, 249\u2013258 (2010).","journal-title":"Influenza and Other Respiratory Viruses"},{"key":"BFsrep18062_CR31","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1017\/S0950268814001447","volume":"143","author":"Y Xiao","year":"2015","unstructured":"Xiao, Y. & Moghadas, S. M. The impact of ethnicity and geographic location of residence on the 2009 influenza H1N1 pandemic vaccination. Epidemiol. Infect. 143, 757\u2013765 (2015).","journal-title":"Epidemiol. Infect"},{"key":"BFsrep18062_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.healthplace.2013.12.005","volume":"26","author":"K Morrison","year":"2014","unstructured":"Morrison, K., Buckeridge, D. L., Xiao, Y. & Moghadas, S. M. The impact of geographical location of residence on disease outcomes among Canadian First Nations populations during the 2009 influenza A(H1N1) pandemic. Health and Place, 26, 53\u201359 (2014).","journal-title":"Health and Place"},{"key":"BFsrep18062_CR33","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nature04017","volume":"437","author":"NM Ferguson","year":"2005","unstructured":"Ferguson, N. M. et al. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437, 209\u2013214 (2005).","journal-title":"Nature"},{"key":"BFsrep18062_CR34","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(06)67970-1","volume":"367","author":"T Jefferson","year":"2006","unstructured":"Jefferson, T. et al. Antivirals for influenza in healthy adults: Systematic review. The Lancet 367, 303\u2013313 (2006).","journal-title":"The Lancet"},{"key":"BFsrep18062_CR35","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/aje\/kwj362","volume":"165","author":"ME Halloran","year":"2007","unstructured":"Halloran, M. E., Hayden, F. G., Yang, Y., Longini Jr., I. M. & Monto, A. S. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am. J. Epidemiol. 165, 212\u2013221 (2007).","journal-title":"Am. J. Epidemiol."},{"key":"BFsrep18062_CR36","unstructured":"Mostaco\u2013Guidolin, L. C., Pizzi, N. J., Demko, A. B. & Moghadas, S. M. A software development framework for agent-based infectious disease modelling, 641\u2013664, Biomedical Engineering, Trends, Researches and Technologies (In-Tech 2011)."},{"key":"BFsrep18062_CR37","unstructured":"Statistics Canada (2007). Manitoba (Code4622048) (Table). 2006 Community Profiles. 2006 Census. Statistics Canada Catalogue no. 92\u2013591-XWE. Ottawa. Released March 13, 2007."},{"key":"BFsrep18062_CR38","unstructured":"Statistics Canada (2007). Winnipeg, Manitoba (Code4611040) (Table). 2006 Community Profiles. 2006 Census. Statistics Canada Catalogue no. 92\u2013591-XWE. Ottawa. Released March 13, 2007."},{"key":"BFsrep18062_CR39","unstructured":"Moghadas, S. M. & Laskowski, M. A logical modelling framework for influenza infection. Project report (2014). Available at: https:\/\/cdn.metricmarketing.ca\/www.nccid.ca\/files\/Influenza\/ModelFrameFLU_FINAL.pdf. (Accessed: 15th May, 2015)."},{"key":"BFsrep18062_CR40","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S1473-3099(09)70069-6","volume":"9","author":"J Lessler","year":"2009","unstructured":"Lessler, J. et al. Incubation periods of acute respiratory viral infections: A systematic review. Lancet Infect. Dis. 9, 291\u2013300 (2009).","journal-title":"Lancet Infect. Dis."},{"key":"BFsrep18062_CR41","doi-asserted-by":"publisher","first-page":"e89651","DOI":"10.1371\/journal.pone.0089651","volume":"9","author":"M Laskowski","year":"2014","unstructured":"Laskowski, M., Greer, A. L. & Moghadas, S. M., Antiviral strategies for emerging influenza viruses in remote communities. PLoS One 9, e89651 (2014).","journal-title":"PLoS One"},{"key":"BFsrep18062_CR42","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/aje\/kwh092","volume":"159","author":"IM Longini Jr","year":"2004","unstructured":"Longini, Jr I. M., Halloran, M. E., Nizam, A. & Yang, Y. Containing pandemic influenza with antiviral agents. Am. J. Epidemiol. 159, 623\u2013633 (2004).","journal-title":"Am. J. Epidemiol."},{"key":"BFsrep18062_CR43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1741-7015-7-73","volume":"7","author":"SM Moghadas","year":"2009","unstructured":"Moghadas, S. M., Bowman, C. S., R\u00f6st, G., Fisman, D. N. & Wu, J. Post\u2013exposure prophylaxis during pandemic outbreaks. BMC Medicine 7, 73 (2009).","journal-title":"BMC Medicine"},{"key":"BFsrep18062_CR44","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(05)17984-7","volume":"365","author":"T Jefferson","year":"2005","unstructured":"Jefferson, T. et al. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. The Lancet 365, 773\u2013780 (2005).","journal-title":"The Lancet"},{"key":"BFsrep18062_CR45","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S0140-6736(06)69294-5","volume":"368","author":"J Lin","year":"2006","unstructured":"Lin, J. et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomized controlled trial. The Lancet 368, 991\u2013997 (2006).","journal-title":"The Lancet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep18062","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep18062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep18062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T07:00:24Z","timestamp":1672902024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep18062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,14]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,11,22]]}},"alternative-id":["BFsrep18062"],"URL":"https:\/\/doi.org\/10.1038\/srep18062","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,14]]},"assertion":[{"value":"17 June 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There is potential competing interest. NC is a member of Medicago Inc., which partially supported this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18062"}}